Details Basic Details Date Friday, September 27, 2019 Medical Product montelukast Singulair Health Outcome(s) inpatient depressive disorder, outpatient depressive disorder, self-harm, suicide Meeting Details View the Advisory Committee Meeting Materials here Additional Information Related Link(s) FDA Safety Communication: FDA requires Boxed Warning for montelukast (Singulair) Sentinel Drug Assessment: Singulair (montelukast) & Neuropsychiatric Adverse Events Consisting of: Inpatient Depressive Disorder, Outpatient Depressive Disorder, Self-Harm, and Suicide Related Assessment(s) Neuropsychiatric Events Following Montelukast Use: A Propensity Score Matched Analysis